Floatz logo

8 assets in Hodgkin'S Lymphoma, Mixed Cellularity

Therapeutic assets addressing Hodgkin'S Lymphoma, Mixed Cellularity, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (69)
Nivestim
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (69)
Bleomycin
Hodgkin'S Lymphoma, Mixed Cellularity
City of Hope Medical CenterP3BB (68)
Brentuximab Vedotin
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (66)
Dacarbazine
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (66)
Vinblastine
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (66)
Nivolumab
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3BB (64)
Pegfilgrastim
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)P3B (60)